What Algopyrin treats: main uses and benefits

The medication is relevant across therapeutic contexts to provide supportive relief for symptoms that create noticeable physiological strain. The medicine plays a role in managing symptoms related to moderate to severe pain and fever. It is commonly used when supportive symptom management is appropriate, including situations involving pain after injury or surgery, or cancer-related discomfort.

The medication is commonly used for the management of symptoms related to acute pain, which covers intense discomfort following injuries, surgical procedures, headaches, and toothaches. The medication is considered relevant for easing symptoms related to heightened physiological activity, specifically discomfort associated with the involuntary tension of smooth muscles, such as renal colic or biliary colic. This supports symptomatic relief by easing the cramping manifestations associated with internal muscle spasm.

“This medication is applied in clinical settings requiring support for symptoms related to systemic imbalance, where additional symptomatic support is needed.”

The therapeutic benefit is assisting with managing these distressing manifestations, which helps improve day-to-day comfort during symptomatic periods when symptoms become more noticeable.

---

Quick Fact: Symptomatic Support for Acute Discomfort and Spasm
Primary Use: Supports symptomatic management in conditions involving episodic or fluctuating manifestations of pain and smooth muscle spasms.

Regulatory References

1. European Medicines Agency (EMA) review

Eligibility Map: Who can and cannot use Algopyrin — Official Regulatory Information

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adults and adolescents 15 years of age or older (or body weight > 53 kg). Children and adolescents up to 14 years old are eligible for weight-based dosing with appropriate formulations.
Populations for whom use is contraindicated	Patients with a history of agranulocytosis induced by metamizole or pyrazolones; impaired bone marrow function; diseases of the haematopoietic system; acute intermittent hepatic porphyria; or congenital glucose-6-phosphate-dehydrogenase deficiency. Use is also contraindicated in infants below 3 months of age or 5 kg body weight.
Pregnancy and lactation eligibility status	Use is contraindicated during the third trimester of pregnancy and while breastfeeding. Single doses during the first two trimesters may be conditionally acceptable if other analgesics are unsuitable.
Eligibility-related restrictions	Patients with impaired renal or hepatic function and older individuals require special caution, as the medicine's elimination may be prolonged. Eligibility is also restricted in cases of known analgesic-induced asthma or intolerance.

---

Eligibility Classifications (High-Level)

Category	Classification
Eligibility severity classification	Absolute Contraindication; Restricted/Conditional Use (Caution); Age/Weight Threshold.
Regulatory basis	European Medicines Agency (EMA) harmonized guidelines.

---

Resulting Eligibility Structure

• The medicine is strictly contraindicated for any individual with a history of blood-cell-related disorders or known pyrazolone hypersensitivity.
• Eligibility is defined by a mandatory minimum threshold of 3 months of age or 5 kg body weight.
• Use is prohibited during the final three months of pregnancy and while breastfeeding due to established risks.

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use the medicine by establishing clear absolute prohibitions based on haematological history and genetic predispositions. The profile further limits eligibility by setting strict age minimums and requiring special caution for conditional populations, such as those with organ dysfunction or in early pregnancy.

Interactions with other medicines and products

The active substance of Algopyrin, Metamizole, has documented interactions with specific medicines and substance categories, primarily through both pharmacodynamic and pharmacokinetic mechanisms.

Clinically Significant Interactions

Metamizole can cause a clinically severe interaction when used with acetylsalicylic acid (aspirin) taken at low doses for cardiovascular protection. The interaction is pharmacodynamic, as Metamizole prevents aspirin from binding to and inhibiting COX-1, thereby reducing its anti-platelet aggregation effect. A delay in administration between the two products is recommended to manage this risk.

Pharmacokinetic Interactions

Metamizole is a moderate to strong inducer of certain liver enzymes, specifically CYP3A4, CYP2B6, and CYP2C19. This induction may result in a decrease in the plasma concentrations of medicines that are substrates for these enzymes, potentially leading to a loss of efficacy. This effect is most relevant when Metamizole is prescribed in high doses (1000 mg three to four times daily) for more than one day. Concomitant use with the immunosuppressant Ciclosporin is known to cause a decrease in its serum levels, requiring therapeutic drug monitoring.

Other Interactions

• Chlorpromazine: Concomitant use may result in an additive effect leading to hypothermia (low body temperature).
• Agranulocytosis-Causing Drugs: Metamizole should be used with caution alongside any other medicinal products that are known to have a risk of causing agranulocytosis (a serious blood disorder).

Algopyrin operates through a dual pharmacodynamic mechanism involving enzyme inhibition and receptor modulation. The primary action is the non-selective inhibition of cyclooxygenase ( COX) enzymes, specifically COX-1 and COX-2. This interaction diminishes the enzymatic conversion of arachidonic acid into prostaglandins, resulting in a change in the level of PGE2 and other lipid mediators involved in local signal transduction.

Secondly, the compound interacts directly with the mathbfGABAA receptor complex, an inhibitory ligand-gated ion channel located in the central and peripheral nervous systems. Binding to this site promotes an increase in chloride ion conductance across the cell membrane, leading to neuronal hyperpolarization.

The combined effect of COX inhibition and mathbfGABAA receptor modulation alters activity within the thermoregulatory center of the hypothalamus. This system-level consequence adjusts heat-regulating mechanisms, including peripheral vasodilation and increased perspiration.

Algopyrin (metamizole sodium) is administered through several established routes to manage acute symptoms.

Approved Administration Routes

Primary routes of administration are defined for the various dosage forms:

Route	Forms Applicable
Oral	Tablets and Oral Solutions.
Intravenous (IV)	Solution for Injection.
Intramuscular (IM)	Solution for Injection.

Standard Dosing and Frequency

Dosing regimens emphasize the use of the lowest effective dose:

• Adult Single Dose: The typical single dose is 500 mg to 1000 mg.
• Dosing Frequency: A single dose may be taken up to 4 times daily, provided there is an interval of 6 to 8 hours between administrations.
• Maximum Daily Dose: The maximum recommended daily dose for oral use is 4000 mg (4 g) for adults and adolescents aged 15 years and older (> 53 kg).

Procedural and Population-Specific Instructions

Instructions for use include specific requirements for proper administration and dose adjustment:

• IV Administration: The injection solution must be administered very slowly, taking at least 3 to 5 minutes per 1000 mg dose. Rapid injection is a documented procedural constraint.
• Oral Intake: Tablets and solutions can generally be taken with or without food.
• Renal/Hepatic Impairment: For individuals with reduced kidney or liver function, multiple high doses should be avoided, and a reduced dose and/or extended dosing interval may be required.
• Older Adults: A reduced dose may also be necessary for older adults due to potential changes in drug clearance.

Research Evidence / Overview of Studies for Algopyrin

This section outlines the types of research that have been conducted on Algopyrin (Metamizole), describing what studies have measured and what remains uncertain. This is a summary of the evidence landscape and should not be used as clinical advice.

---

Evidence for Use in Acute Pain and Spasm

The most substantial research on Algopyrin has been used in research exploring how symptoms change over time in acute situations. These studies primarily use structured short-term Randomized Controlled Trials (RCTs) and meta-analyses, where researchers compare the drug's measured outcomes to an inactive treatment (placebo) or to other symptom-management options. The research has focused on outcomes related to physical discomfort and outcomes describing episodic or acute changes in contexts that involve temporary, acute physical discomfort, such as following surgical procedures or pain associated with smooth muscle contractions like renal or biliary colic.

Studies on Post-Operative Pain Relief

Research has extensively studied Algopyrin's role in patients following various surgical procedures. Studies observed that findings describe patterns observed in the studies regarding symptom pattern changes, and also collected data on how often patients required additional medication to address the persistent physical discomfort.

Studies on Pain from Smooth Muscle Spasm (Colic)

Algopyrin was evaluated in settings involving smooth muscle spasm, specifically for conditions associated with acute or disruptive episodes like renal colic or biliary colic. The data show patterns related to symptom evolution in the acute setting when compared to some other drugs used for colic. However, comparative evidence is lacking against every available standard treatment, and limited information is available for long-term outcomes.

Evidence for Use in Fever and Chronic Discomfort

Research has also examined Algopyrin for outcomes related to systemic or functional imbalance, such as fever. Its role in research contexts involving fever and its explored, though more limited, role in chronic or subacute pain scenarios has also been studied.

Studies on Temperature-Related Outcomes (Fever)

Algopyrin was studied for exploring measured changes in elevated body temperature. The findings indicate patterns regarding the measured temperature decrease in the observed populations. However, evidence is limited from recent, large-scale, high-quality comparative RCTs that examine its use specifically in a broad range of adult febrile populations.

---

Long-Term Studies and Durability of Effect

Most of the available evidence concerning Algopyrin focusing on episodes where symptoms become more noticeable (acute pain, fever) is derived from trials with follow-up durations were limited. The research provides context for short-term observations, but the scope of long-term findings is not fully defined. For research into any chronic condition, data are still emerging, and the evidence is characterized by a lack of long-term data.

Key Studies & References

1. Metamizole (Dipyrone): LiverTox - Clinical and Research Information on Drug-Induced Liver Injury
2. PubMed Database (Implied source for existence of primary clinical trials and observational studies)
3. National Institute for Health and Care Excellence (NICE) Clinical Guidelines (Implied source for clinical context and guidelines)

Common questions about Algopyrin (FAQ)

Q: How quickly does Algopyrin start to work and how long does the effect last?

Official product information indicates that the pain-relieving effects of the active ingredient typically begin within 30 minutes following oral administration. The duration of the analgesic effect generally lasts for approximately 4 hours. This timeline represents general expectations described in official documents.

Q: What common stomach side effects are associated with Algopyrin?

Official labeling does not typically list major gastrointestinal events among the most frequent adverse reactions for Algopyrin. However, official information lists possible gastrointestinal adverse effects which can include symptoms such as nausea, vomiting, or stomach pain.

Q: Does Algopyrin cause drowsiness, and can I drive or operate machinery after taking it?

Official documents include a warning regarding possible effects on reaction capacity. This warning is included because such effects could impact activities requiring concentration, such as driving or operating complex machinery. These effects are considered rare, especially when taking higher doses.

Q: Can I take Algopyrin with food, or should it be taken on an empty stomach?

According to the official product information, oral forms of Algopyrin are generally effective whether taken with or without food. However, taking the medicine with a meal may result in a slight delay in the onset of the medicine's action.

Q: Can I take Algopyrin if I am also taking an antibiotic?

Regulatory documents contain information stating that co-administration of metamizole (the active ingredient) and certain antibiotics has been associated with a specific safety concern. This combination may potentially mask the early symptoms of a rare but serious side effect called agranulocytosis, which involves a decrease in white blood cells.

Q: Does Algopyrin interact with blood pressure medications?

Regulatory information explicitly states that metamizole has been reported to decrease the activity of some antihypertensive medications (drugs used to treat high blood pressure). Evidence indicates that this interference may affect specific drugs such as captopril, triamterene, and amlodipine.

Q: Is there a risk of liver problems with Algopyrin?

Official reports indicate that inflammation of the liver, known as hepatitis, has been reported in patients using this medicine. Symptoms of liver issues may develop within a few days to a few months of use. The official product information lists specific signs of liver injury, such as feeling sick, fever, dark-colored urine, or yellowing of the skin, that have been associated with these reports.

Q: Is Algopyrin an anti-inflammatory drug, similar to ibuprofen or naproxen?

Algopyrin’s active ingredient, metamizole, is officially classified as a pyrazolone derivative, recognized for its analgesic, antipyretic, and spasmolytic effects. While it affects the body’s pain and temperature pathways, official product information indicates that it possesses only weak anti-inflammatory properties.

Official Storage Conditions

Labeled Storage Temperature Requirements	Store at a temperature below 25 C.
Light/Moisture Protection Requirements	Protect from light and store in the original package.
Handling Requirements	Do not freeze the medicine.
Child-Protection Storage Requirements	Keep medicines out of the sight and reach of children.

Official Disposal Instructions

Regulatory guidelines define mandatory steps for discarding unused or expired product. The preferred method is using a drug take-back program or specialized collection service, which ensures proper pharmaceutical waste handling. If a take-back option is unavailable, the medicine should be prepared for household trash disposal by mixing it with an undesirable substance (e.g., used coffee grounds) in a sealed container. The product must not be disposed of in wastewater (flushed down a toilet or poured down a drain) unless explicitly directed by the product labeling. Disposal must always be carried out according to local requirements for pharmaceutical waste.